Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 0.73 |
| ▸ | AKT1 | P31749 | 2/20 | 0.72 |
| ▸ | AKT2 | P31751 | 2/20 | 0.72 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5778025 | 0.95 | OPRM1 (0.91) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL8863557 | 0.95 | OPRM1 (0.91) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL11223608 | 0.92 | OPRM1 (0.86) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL3634015 | 0.91 | OPRM1 (0.83) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL20763210 | 0.90 | OPRM1 (1.00) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL1436457 | 0.89 | OPRM1 (0.79) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL6496007 | 0.88 | OPRM1 (0.83) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL5777954 | 0.87 | OPRM1 (0.77) | OPRM1OPRK1OPRL1DRD4CHRM1 | |
| SCHEMBL5774325 | 0.87 | OPRM1 (0.78) | OPRM1OPRK1OPRL1DRD4AKT1 | |
| SCHEMBL7849321 | 0.87 | OPRM1 (1.00) | OPRM1OPRK1OPRL1DRD4AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4353713-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Kinki University (JP) | 2024-04-17 | — | — | EP | claimed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | claimed |
| EP-2155676-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | Commissariat à l'Energie Atomique (FR) | 2010-02-24 | — | — | EP | claimed |
| WO-2008146172-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | WO | claimed |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4353713-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Kinki University (JP) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | disclosed |
| EP-2357172-B1 | Process for the preparation of pimozide | INST UNIV CIENCIA I TECNOLOGIA (ES) | 2012-10-31 | — | — | EP | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| EP-0990653-B1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-6258825-B1 | ANALGESIC, A RELIEVER AGAINST TOLERANCE TO A NARCOTIC ANALGESIC REPRESENTED BY MORPHINE, REMEDY FOR PARKINSONISM, A REMEDY FOR CHOREA, AN ANTIDEPRESSANT, A REMEDY FOR DIABETES INSIPIDUS, A REMEDY FOR POLYURIA, OR HYPOTENSION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | OPRM1 4585/4885OPRK1 4261/4885OPRL1 4337/4885 |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1G, CACNA1I, CACNA1H | OPRM1 877/4885OPRK1 739/4885OPRL1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.